Moderna and CytomX partner for mRNA-based conditnionally activated therapeutics
Collaboration to generate and develop therapeutics for oncology and non-oncology conditions
Collaboration to generate and develop therapeutics for oncology and non-oncology conditions
The PharmaEssentia Innovation Research Center (PIRC) will advance the company’s diverse pipeline and research footprint in the U.S., driving job creation
Advanz Pharma will leverage its specialty, hospital, and rare disease expertise and infrastructure to commercialize AT-007 in Europe for both Galactosemia and SORD Deficiency
Cipla and Ethris partner for the development of mRNA-based therapies
Advent will also be making an open offer to acquire additional 26% of the outstanding equity shares of the company from the public shareholders.
LG Chem will receive totaling up to $95.5 million for the China rights
The investment will enable the company to enter European markets as well as enhance margins in current markets
Sanjeev is currently the Country President for AstraZeneca Malaysia
Subscribe To Our Newsletter & Stay Updated